Trevi Therapeutics, Inc. (TRVI) vs Zymeworks Inc. (ZYME)
A side-by-side comparison of Trevi Therapeutics, Inc. and Zymeworks Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
TRVI
Trevi Therapeutics, Inc.
$13.18HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZYME
Zymeworks Inc.
$25.65HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — TRVI vs ZYME
growth of $100 · dividends reinvested · last 7yTRVI +73.9% (+8.2%/yr)ZYME +37.2% (+4.6%/yr)TRVI compounded faster over this window
TRVI ZYME
TRVI vs ZYME: by the numbers
- •ZYME is the larger company ($1.89B vs $1.87B market cap).
- •Both run net losses; TRVI's is the smaller (0.00% vs -404.00% net margin).
Metrics side by side
Valuation
| Metric | TRVI | ZYME |
|---|---|---|
| Forward P/E | N/A | 24.73 |
| P/S ratio | N/A | 50.83 |
| P/B ratio | 5.82 | 23.48 |
Profitability
| Metric | TRVI | ZYME |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -87.33% |
| Net margin | 0.00% | -404.00% |
| ROE | -15.90% | -186.63% |
| ROIC | -18.51% | -44.06% |
Growth (annualized)
| Metric | TRVI | ZYME |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.35% |
| Total return CAGR (5Y) | 61.74% | -1.37% |
Frequently asked
- How have TRVI and ZYME total returns compared?
- Over the past 5 years, TRVI delivered 61.74% and ZYME delivered -1.37% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.